
Commentary|Videos|November 22, 2024
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Author(s)Rimas V. Lukas, MD
Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Advertisement
Rimas V. Lukas, MD, neuro-oncologist, associate professor, Neurology, Northwestern University Feinberg School of Medicine, discusses key efficacy data and implications from the phase 3 STELLAR trial (NCT02796261) evaluating eflornithine plus lomustine vs lomustine in patients with recurrent IDH-mutant anaplastic astrocytoma per 2021 World Health Organization diagnostic criteria.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































